keyword
MENU ▼
Read by QxMD icon Read
search

non hodgkin lymphoma

keyword
https://www.readbyqxmd.com/read/29456795/discovery-of-ebi-2511-a-highly-potent-and-orally-active-ezh2-inhibitor-for-the-treatment-of-non-hodgkin-s-lymphoma
#1
Biao Lu, Xiaodong Shen, Lei Zhang, Dong Liu, Caihua Zhang, Jingsong Cao, Ru Shen, Jiayin Zhang, Dan Wang, Hong Wan, Zhibin Xu, Ming-Hsun Ho, Minsheng Zhang, Lianshan Zhang, Feng He, Weikang Tao
A novel series of benzofuran derived EZH2 inhibitors were discovered through a scaffold hopping approach based on the clinical compound of EPZ-6438. Further rational structure-activity relationship exploration and optimization led to the discovery of more potent EZH2 inhibitors with oral bioavailability in mice and rats. A lead compound EBI-2511 (compound 34 ) demonstrated excellent in vivo efficacy in Pfeiffer tumor Xenograft models in mouse and is under preclinical development for the treatment of cancers associated with EZH2 mutations...
February 8, 2018: ACS Medicinal Chemistry Letters
https://www.readbyqxmd.com/read/29456616/the-mortality-incidence-ratio-as-an-indicator-of-five-year-cancer-survival-in-metropolitan-lima
#2
Karoline Stenning-Persivale, Maria Jose Savitzky Franco, Alejandra Cordero-Morales, José Cruzado-Burga, Ebert Poquioma, Edgar Díaz Nava, Eduardo Payet
Introduction: The Mortality-Incidence Ratio complement [1 - MIR] is an indicator validated in various populations to estimate five-year cancer survival, but its validity remains unreported in Peru. This study aims to determine if the MIR correlates directly with five-year survival in patients diagnosed with the ten most common types of cancer in metropolitan Lima. Materials and methods: The Metropolitan Lima Cancer Registry (RCLM in Spanish) for 2004-2005 was used to determine the number of new cases and the number of deaths of the following cancers: breast, stomach, prostate, thyroid, lung, colon, cervical, and liver cancers, as well as non-Hodgkin's lymphoma and leukaemia...
2018: Ecancermedicalscience
https://www.readbyqxmd.com/read/29456131/high-expression-of-cc-chemokine-receptor-5-ccr5-promotes-disease-progression-in-patients-with-b-cell-non-hodgkin-lymphomas
#3
Aleksandra Butrym, Ilona Kryczek, Dorota Dlubek, Emilia Jaskula, Andrzej Lange, Artur Jurczyszyn, Grzegorz Mazur
Chemokines are small proteins, that regulate cell migration in many physiological and pathologic processes in human body. They are also responsible for cancer progression. CC chemokine receptor 5 (CCR5) is responsible for cell recruitment in inflammation and may be involved in antitumor immune response controlling. Aberrant CCR5 can be found in different kind of cancers, not only hematological, but also solid tumors. Non-Hodgkin lymphomas consist of many lymphoma subtypes. They predominantly derive from B cells and can have very heterogenous clinical course...
January 10, 2018: Current Problems in Cancer
https://www.readbyqxmd.com/read/29453628/safety-tolerability-and-preliminary-activity-of-imgn529-a-cd37-targeted-antibody-drug-conjugate-in-patients-with-relapsed-or-refractory-b-cell-non-hodgkin-lymphoma-a-dose-escalation-phase-i-study
#4
Anastasios Stathis, Ian W Flinn, Sumit Madan, Kami Maddocks, Arnold Freedman, Steven Weitman, Emanuele Zucca, Mihaela C Munteanu, M Lia Palomba
Background CD37 is expressed on B-cell lymphoid malignancies, thus making it an attractive candidate for targeted therapy in non-Hodgkin lymphoma (NHL). IMGN529 is an antibody-drug conjugate comprising a CD37-binding antibody linked to the maytansinoid DM1, a potent anti-mitotic agent. Methods This first-in-human, phase 1 trial recruited adult patients with relapsed or refractory B-cell NHL. The primary objective was to determine the maximum tolerated dose (MTD) and recommended phase 2 dose. Secondary objectives were to evaluate safety, pharmacokinetics, and preliminary clinical activity...
February 17, 2018: Investigational New Drugs
https://www.readbyqxmd.com/read/29452969/breast-necrosis-in-a-patient-with-primary-t-cell-non-hodgkin-lymphoma
#5
Ana Alicia Tejera Hernández, Joaquín Gómez Ramírez, Sonia Rivas Fidalgo, María Luisa Sánchez de Molina Ramperez, Mariano Díaz Miguel
No abstract text is available yet for this article.
February 13, 2018: Cirugía Española
https://www.readbyqxmd.com/read/29452665/novel-agents-for-relapsed-and-refractory-follicular-lymphoma
#6
REVIEW
Chan Yoon Cheah, Nathan H Fowler
Follicular lymphoma is one of the most common non-Hodgkin's lymphomas. Although current frontline regimens are associated with high response rates, most patients still relapse. When progression is discovered, re-establishing the diagnosis and ruling out transformation in paramount. The outcomes following relapse have been improving due to the activity and increasing availability of novel agents with various mechanisms of action. Despite these advances, single agent activity is limited and the disease remains incurable in the majority of cases...
March 2018: Best Practice & Research. Clinical Haematology
https://www.readbyqxmd.com/read/29452663/management-of-untreated-advanced-stage-follicular-lymphoma-role-of-patient-discernment
#7
REVIEW
Jayadev Manikkam Umakanthan, Mathew A Lunning
Follicular lymphoma is the most common indolent non-Hodgkin lymphoma. Advanced stage disease is common at diagnosis. The timing of treatment for follicular lymphoma is best approached by considering the combination of presence or absence of symptoms along with estimation of tumor burden. Upfront treatment strategies should take into initial presentation variables, pace of disease progression and goals of care after discussion with the patient. Treatment approaches remain diverse and patient discernment is paramount...
March 2018: Best Practice & Research. Clinical Haematology
https://www.readbyqxmd.com/read/29452660/novel-therapies-for-relapsed-refractory-mantle-cell-lymphoma
#8
REVIEW
Puja C Arora, Craig A Portell
Mantle cell lymphoma is an aggressive Non-Hodgkin's lymphoma that is considered incurable with standard therapies. Most patients treated with frontline immunochemotherapy relapse within a few years and do not usually respond to salvage chemotherapy. Persistent activation of the B-cell receptor pathway is critical to the pathogenesis of mantle cell lymphoma. Inhibition of Bruton's tyrosine kinase, an essential B-cell receptor pathway component with ibrutinib has shown clinical activity and has changed how MCL is treated in the relapsed/refractory setting...
March 2018: Best Practice & Research. Clinical Haematology
https://www.readbyqxmd.com/read/29444231/phase-iia-study-of-the-cd19-antibody-mor208-in-patients-with-relapsed-or-refractory-b-cell-non-hodgkin-s-lymphoma
#9
W Jurczak, P L Zinzani, G Gaidano, A Goy, M Provencio, Z Nagy, T Robak, K Maddocks, C Buske, S Ambarkhane, M Winderlich, M Dirnberger-Hertweck, R Korolkiewicz, K A Blum
Background: This two-stage, phase IIa study (ClinicalTrials.gov: NCT01685008) investigated the antitumor activity and safety of MOR208, an Fc-engineered, humanized, CD19 antibody, in patients with relapsed or refractory (R-R) B-cell non-Hodgkin's lymphoma (NHL). CD19 is broadly expressed across the B-lymphocyte lineage, including in B-cell malignancies, but not by hematological stem cells. Patients and methods: Patients aged ≥18 years, with R-R NHL progressing after ≥1 prior rituximab containing regimen were enrolled into subtype-specific cohorts: diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), other indolent (i)NHL and mantle cell lymphoma (MCL)...
February 9, 2018: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/29444176/lack-of-usefulness-of-computed-tomography-for-surveillance-in-patients-with-aggressive-non-hodgkin-lymphoma
#10
Ka-Won Kang, Se Ryeon Lee, Dae Sik Kim, Eun Sang Yu, Hwa Jung Sung, Seok Jin Kim, Chul Won Choi, Yong Park, Byung Soo Kim
Surveillance computed tomography (CT) is usual practice for patients with aggressive non-Hodgkin lymphoma (aNHL) in complete remission (CR). However, evidence to support this strategy is lacking. We retrospectively analyzed our institutional lymphoma registry, including patients with lymphoma consecutively enrolled from June 1995 to October 2016. Of 1,385 patients with aNHL, 664 achieved CR and were followed up with or without surveillance CT. Surveillance CT was performed for 609 patients every 3 or 6 months for the first 2 years, then every 6 or 12 months thereafter...
2018: PloS One
https://www.readbyqxmd.com/read/29439188/incidence-and-risk-factors-for-relapses-in-hiv-associated-non-hodgkin-lymphoma-as-observed-in-the-german-hiv-related-lymphoma-cohort-study
#11
Philipp Schommers, Daniel Gillor, Marcus Hentrich, Christoph Wyen, Timo Wolf, Mark Oette, Alexander Zoufaly, Jan-Christian Wasmuth, Johannes R Bogner, Marcus Müller, Stefan Esser, Alisa Schleicher, Bjöern Jensen, Albrecht Stoehr, Georg Behrens, Alexander Schultze, Jan Siehl, Jan Thoden, Ninon Taylor, Christian Hoffmann
Outcome of HIV-infected patients with AIDS-related lymphomas has improved during recent years. However, data on incidence, risk factors, and outcome of relapses in AIDS-related lymphomas after achieving complete remission are still limited. This prospective observational multicenter study includes HIV-infected patients with biopsy- or cytology proven malignant lymphomas since 2005. Data on HIV infection and lymphoma characteristics, treatment and outcome were recorded. For this analysis, AIDS-related lymphomas patients in complete remission were analyzed in terms of their relapse-free survival and potential risk factors for relapses...
February 8, 2018: Haematologica
https://www.readbyqxmd.com/read/29439173/nccn-guidelines-insights-t-cell-lymphomas-version-2-2018
#12
Steven M Horwitz, Stephen M Ansell, Weiyun Z Ai, Jeffrey Barnes, Stefan K Barta, Michael Choi, Mark W Clemens, Ahmet Dogan, John P Greer, Ahmad Halwani, Bradley M Haverkos, Richard T Hoppe, Eric Jacobsen, Deepa Jagadeesh, Youn H Kim, Matthew A Lunning, Amitkumar Mehta, Neha Mehta-Shah, Yahurio Oki, Elise A Olsen, Barbara Pro, Saurabh A Rajguru, Satish Shanbhag, Andrei Shustov, Lubomir Sokol, Pallawi Torka, Ryan Wilcox, Basem William, Jasmine Zain, Mary A Dwyer, Hema Sundar
Natural killer (NK)/T-cell lymphomas are a rare and distinct subtype of non-Hodgkin's lymphomas. NK/T-cell lymphomas are predominantly extranodal and most of these are nasal type, often localized to the upper aerodigestive tract. Because extranodal NK/T-cell lymphomas (ENKL) are rare malignancies, randomized trials comparing different regimens have not been conducted to date and standard therapy has not yet been established for these patients. These NCCN Guidelines Insights discuss the recommendations for the diagnosis and management of patients with ENKL as outlined in the NCCN Guidelines for T-Cell Lymphomas...
February 2018: Journal of the National Comprehensive Cancer Network: JNCCN
https://www.readbyqxmd.com/read/29435074/over-activated-pd-1-pd-l1-axis-facilitates-the-chemoresistance-of-diffuse-large-b-cell-lymphoma-cells-to-the-chop-regimen
#13
Juan Liu, Lina Quan, Chunhui Zhang, Aichun Liu, Dongxia Tong, Jinghua Wang
Interaction between the programmed cell death ligand 1 (PD-L1) and programmed cell death 1 (PD-1) contributes to tumor cell resistance to chemotherapeutic agents. PD-L1 is expressed in the cells of diffuse large B-cell lymphoma (DLBCL), one common type of malignant non-Hodgkin lymphomas. However, little is known about how the PD-1/PD-L1 pathway functions in the pathogenesis of DLBCL. Therefore, the present study investigated whether and how the PD-1/PD-L1 axis is involved in regulating the sensitivity of CRL2631, a DLBCL cell line, to the CHOP (Cyclophosphamide, Hydroxydaunorubicin/adriamycin, Oncovin/vincristine and Prednisone) chemotherapeutic regimen...
March 2018: Oncology Letters
https://www.readbyqxmd.com/read/29434048/hospital-end-of-life-care-in-haematological-malignancies
#14
Yvan Beaussant, Etienne Daguindau, Adrien Chauchet, Philippe Rochigneux, Christophe Tournigand, Régis Aubry, Lucas Morin
OBJECTIVE: To investigate patterns of care during the last months of life of hospitalised patients who died from different haematological malignancies. METHODS: Nationwide register-based study, including all hospitalised adults ≥20 years who died from haematological malignancies in France in 2010-2013. Outcomes included use of invasive cancer treatments and referral to palliative care. Percentages are adjusted for sex and age using direct standardisation. RESULTS: Of 46 629 inpatients who died with haematological malignancies, 24...
February 6, 2018: BMJ Supportive & Palliative Care
https://www.readbyqxmd.com/read/29433938/b-cell-lymphoma-immunotherapy-using-tlr9-targeted-oligonucleotide-stat3-inhibitors
#15
Xingli Zhao, Zhuoran Zhang, Dayson Moreira, Yu-Lin Su, Haejung Won, Tomasz Adamus, Zhenyuan Dong, Yong Liang, Hongwei H Yin, Piotr Swiderski, Raju K Pillai, Larry Kwak, Stephen Forman, Marcin Kortylewski
Growing evidence links the aggressiveness of non-Hodgkin's lymphoma, especially the activated B cell-like type diffuse large B cell lymphomas (ABC-DLBCLs) to Toll-like receptor 9 (TLR9)/MyD88 and STAT3 transcription factor signaling. Here, we describe a dual-function molecule consisting of a clinically relevant TLR9 agonist (CpG7909) and a STAT3 inhibitor in the form of a high-affinity decoy oligodeoxynucleotide (dODN). The CpG-STAT3dODN blocked STAT3 DNA binding and activity, thus reducing expression of downstream target genes, such as MYC and BCL2L1, in human and mouse lymphoma cells...
January 17, 2018: Molecular Therapy: the Journal of the American Society of Gene Therapy
https://www.readbyqxmd.com/read/29432597/identification-of-novel-recurrent-etv6-igh-fusions-in-primary-central-nervous-system-lymphoma
#16
Aurélie Bruno, Karim Labreche, Maïlys Daniau, Blandine Boisselier, Guillaume Gauchotte, Louis Royer-Perron, Amithys Rahimian, Frédéric Lemoine, Pierre de la Grange, Justine Guégan, Franck Bielle, Marc Polivka, Clovis Adam, David Meyronet, Dominique Figarella-Branger, Chiara Villa, Fabrice Chrétien, Sandrine Eimer, Frédéric Davi, Audrey Rousseau, Caroline Houillier, Carole Soussain, Karima Mokhtari, Khê Hoang-Xuan, Agusti Alentorn
Background: Primary central nervous system lymphoma (PCNSL) represents a particular entity within non-Hodgkin lymphomas and is associated with poor outcome. The present study addresses the potential clinical relevance of chimeric transcripts in PCSNL discovered by using RNA-sequencing (RNA-Seq). Methods: Seventy-two immunocompetent and newly diagnosed PCNSL cases were included in the present study. Among them, six were analyzed by RNA-seq to detect new potential fusion transcripts...
February 8, 2018: Neuro-oncology
https://www.readbyqxmd.com/read/29429967/primary-central-nervous-system-vasculitis-associated-with-lymphoma
#17
Carlo Salvarani, Robert D Brown, Teresa J H Christianson, John Huston, Stephen M Ansell, Caterina Giannini, Gene G Hunder
OBJECTIVES: To record the clinical findings, response to therapy, and course of patients with primary CNS vasculitis (PCNSV) associated with lymphoma. PATIENTS AND METHODS: We reviewed the histories of 936 patients with a diagnosis of any type of vasculitis and lymphoma who were seen at the Mayo Clinic over a 32-year period. Ten patients with both PCNSV and lymphoma were identified. We compared the findings in these 10 patients with those from 158 patients with PCNSV without lymphoma seen over 29 years...
February 2, 2018: Neurology
https://www.readbyqxmd.com/read/29427399/the-utility-of-bone-marrow-sampling-in-the-diagnosis-and-staging-of-lymphoma-in-south-africa
#18
L Phillips, J Opie
INTRODUCTION: The bone marrow biopsy (BMB) is a diagnostic and staging tool in lymphoma that remains practically useful and relevant in resource-constrained settings, despite restricted applications in international staging guidelines, which favour less invasive nuclear medicine techniques. METHODS: Retrospective laboratory data review of BMBs in adult lymphoma patients from 2005 to 2010 to determine subtypes, rates of bone marrow involvement (BMI), human immunodeficiency virus (HIV) seroprevalence and CD4 counts, trephine length and additional findings...
February 10, 2018: International Journal of Laboratory Hematology
https://www.readbyqxmd.com/read/29427203/cardiovascular-disease-incidence-in-adolescent-and-young-adult-cancer-survivors-a-retrospective-cohort-study
#19
Theresa H M Keegan, Lawrence H Kushi, Qian Li, Ann Brunson, X Chawla, Helen K Chew, Marcio Malogolowkin, Ted Wun
PURPOSE: Few population-based studies have focused on cardiovascular disease (CVD) risk in adolescent and young adult (AYA; 15-39 years) cancer survivors and none have considered whether CVD risk differs by sociodemographic factors. METHODS: Analyses focused on 79,176 AYA patients diagnosed with 14 first primary cancers in 1996-2012 and surviving > 2 years after diagnosis with follow-up through 2014. Data were obtained from the California Cancer Registry and State hospital discharge data...
February 9, 2018: Journal of Cancer Survivorship: Research and Practice
https://www.readbyqxmd.com/read/29427192/community-acquired-respiratory-infections-are-common-in-patients-with-non-hodgkin-lymphoma-and-multiple-myeloma
#20
Noa Lavi, Irit Avivi, Zipora Kra-Oz, Ilana Oren, Emilia Hardak
PURPOSE: Available data suggest that respiratory infections are associated with increased morbidity and mortality in patients hospitalized due to acute leukemia and allogeneic stem cell transplantation (allo-SCT). However, the precise incidence, risk factors, and severity of respiratory infection, mainly community-acquired, in patients with lymphoma and multiple myeloma (MM) are not fully determined. The current study aimed to investigate risk factors for respiratory infections and their clinical significance in patients with B cell non-Hodgkin lymphoma (NHL) and multiple myeloma (MM) in the first year of diagnosis...
February 9, 2018: Supportive Care in Cancer: Official Journal of the Multinational Association of Supportive Care in Cancer
keyword
keyword
29538
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"